-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, Incyte announced that the U.
It is worth noting that Opzelura is the first and only topical JAK inhibitor approved by the US FDA
However, a large number of studies have shown that dysregulation of the JAK-STAT pathway can cause the corresponding symptoms in patients with atopic dermatitis, including itching, inflammation and skin barrier dysfunction
The test results showed that the most common (≥1%) adverse reactions in patients receiving Opzelura were nasopharyngitis, diarrhea, bronchitis, ear infections, increased eosinophil count, urticaria, folliculitis, tonsillitis, and rhinorrhea
Todd Edwards, head of Incyte's inflammation and autoimmunity business unit, told investors in a conference call on Wednesday that, despite the black box warning, Incyte expects Opzelura's peak sales to reach at least $1.
Wall Street also expects Opzelura cream to reach 1.
Evercore ISI analysts recently pointed out that Opzelura is widely regarded as a key asset developed by Incyte to compensate for the loss of patent rights for its oral drug Jakafi in 2027
In general, it is difficult for analysts to give clear answers on the future performance of Opzelura cream
But on the other hand, given the power of Opzelura and the lack of topical options, doctors seem to show enthusiasm for the cream again
In addition, the U.
Reference source:
1.
2.
